Cargando…

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial

AIMS: To compare efficacy and safety of two, once-daily basal insulin formulations [insulin lispro protamine suspension (ILPS) vs. insulin glargine (glargine)] added to oral antihyperglycaemic medications (OAMs) and exenatide BID in suboptimally controlled type 2 diabetes (T2D) patients. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakaki, R F, Blevins, T C, Wise, J K, Liljenquist, D R, Jiang, H H, Jacobson, J G, Martin, S A, Jackson, J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237556/
https://www.ncbi.nlm.nih.gov/pubmed/24298995
http://dx.doi.org/10.1111/dom.12242
_version_ 1782345370091651072
author Arakaki, R F
Blevins, T C
Wise, J K
Liljenquist, D R
Jiang, H H
Jacobson, J G
Martin, S A
Jackson, J A
author_facet Arakaki, R F
Blevins, T C
Wise, J K
Liljenquist, D R
Jiang, H H
Jacobson, J G
Martin, S A
Jackson, J A
author_sort Arakaki, R F
collection PubMed
description AIMS: To compare efficacy and safety of two, once-daily basal insulin formulations [insulin lispro protamine suspension (ILPS) vs. insulin glargine (glargine)] added to oral antihyperglycaemic medications (OAMs) and exenatide BID in suboptimally controlled type 2 diabetes (T2D) patients. METHODS: This 24-week, open-label, multicentre trial randomized patients to bedtime ILPS (n = 171) or glargine (n = 168). Non-inferiority of ILPS versus glargine was assessed by comparing the upper limit of 95% confidence intervals (CIs) for change in haemoglobin A1c (HbA1c) from baseline to week 24 (adjusted for baseline HbA1c) with non-inferiority margin 0.4%. RESULTS: Non-inferiority of ILPS versus glargine was demonstrated: least-squares mean between-treatment difference (ILPS minus glargine) (95% CI) was 0.22% (0.06, 0.38). Mean HbA1c reduction was less for ILPS- versus glargine-treated patients (−1.16 ± 0.84 vs. −1.40 ± 0.97%, p = 0.008). Endpoint HbA1c < 7.0% was achieved by 53.7% (ILPS) and 61.7% (glargine) (p = NS). Overall hypoglycaemia rates (p = NS) and severe hypoglycaemia incidence (p = NS) were similar. Nocturnal hypoglycaemia rate was higher in patients treated with ILPS versus glargine (p = 0.004). Weight gain was similar between groups (ILPS: 0.27 ± 3.38 kg; glargine: 0.66 ± 3.93 kg, p = NS). Endpoint total insulin doses were lower in patients treated with ILPS versus glargine (0.30 ± 0.17 vs. 0.37 ± 0.17 IU/kg/day, p < 0.001). CONCLUSIONS: ILPS was non-inferior to glargine for HbA1c change over 24 weeks, but was associated with less HbA1c reduction and more nocturnal hypoglycaemia. Treat-to-target basal insulin therapy improves glycaemic control and is associated with minimal weight gain when added to OAMs and exenatide BID for suboptimally controlled T2D.
format Online
Article
Text
id pubmed-4237556
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42375562014-12-15 Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial Arakaki, R F Blevins, T C Wise, J K Liljenquist, D R Jiang, H H Jacobson, J G Martin, S A Jackson, J A Diabetes Obes Metab Original Articles AIMS: To compare efficacy and safety of two, once-daily basal insulin formulations [insulin lispro protamine suspension (ILPS) vs. insulin glargine (glargine)] added to oral antihyperglycaemic medications (OAMs) and exenatide BID in suboptimally controlled type 2 diabetes (T2D) patients. METHODS: This 24-week, open-label, multicentre trial randomized patients to bedtime ILPS (n = 171) or glargine (n = 168). Non-inferiority of ILPS versus glargine was assessed by comparing the upper limit of 95% confidence intervals (CIs) for change in haemoglobin A1c (HbA1c) from baseline to week 24 (adjusted for baseline HbA1c) with non-inferiority margin 0.4%. RESULTS: Non-inferiority of ILPS versus glargine was demonstrated: least-squares mean between-treatment difference (ILPS minus glargine) (95% CI) was 0.22% (0.06, 0.38). Mean HbA1c reduction was less for ILPS- versus glargine-treated patients (−1.16 ± 0.84 vs. −1.40 ± 0.97%, p = 0.008). Endpoint HbA1c < 7.0% was achieved by 53.7% (ILPS) and 61.7% (glargine) (p = NS). Overall hypoglycaemia rates (p = NS) and severe hypoglycaemia incidence (p = NS) were similar. Nocturnal hypoglycaemia rate was higher in patients treated with ILPS versus glargine (p = 0.004). Weight gain was similar between groups (ILPS: 0.27 ± 3.38 kg; glargine: 0.66 ± 3.93 kg, p = NS). Endpoint total insulin doses were lower in patients treated with ILPS versus glargine (0.30 ± 0.17 vs. 0.37 ± 0.17 IU/kg/day, p < 0.001). CONCLUSIONS: ILPS was non-inferior to glargine for HbA1c change over 24 weeks, but was associated with less HbA1c reduction and more nocturnal hypoglycaemia. Treat-to-target basal insulin therapy improves glycaemic control and is associated with minimal weight gain when added to OAMs and exenatide BID for suboptimally controlled T2D. Blackwell Publishing Ltd 2014-06 2013-12-29 /pmc/articles/PMC4237556/ /pubmed/24298995 http://dx.doi.org/10.1111/dom.12242 Text en © 2013 The Authors. Diabetes, Obesity and Metabolism published by JohnWiley & Sons Ltd. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Arakaki, R F
Blevins, T C
Wise, J K
Liljenquist, D R
Jiang, H H
Jacobson, J G
Martin, S A
Jackson, J A
Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
title Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
title_full Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
title_fullStr Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
title_full_unstemmed Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
title_short Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
title_sort comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237556/
https://www.ncbi.nlm.nih.gov/pubmed/24298995
http://dx.doi.org/10.1111/dom.12242
work_keys_str_mv AT arakakirf comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT blevinstc comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT wisejk comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT liljenquistdr comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT jianghh comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT jacobsonjg comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT martinsa comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial
AT jacksonja comparisonofinsulinlisproprotaminesuspensionversusinsulinglargineoncedailyaddedtooralantihyperglycaemicmedicationsandexenatideintype2diabetesaprospectiverandomizedopenlabeltrial